Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This study aimed to evaluate the therapeutic potential and synergistic effects of a triple-modality treatment comprising gemcitabine (GEM), calcitriol (CAL), and hyperthermia (HT) in preclinical models of pancreatic and breast cancer.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Three cell lines were used in in vitro experiments: PANC-1 human pancreatic ductal adenocarcinoma (ATCC®), Panc02 murine pancreatic adenocarcinoma (DCTD Repository at Frederic National Laboratory for Cancer Research) and 4T1 mouse triple-negative breast cancer cells (ATCC®).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Calcitriol and hyperthermia potentiate gemcitabine efficacy: A Multifactorial Preclinical Evaluation in Pancreatic and Breast Cancer

Study design awaiting verification · Research Square · 2025

Original publication title

Calcitriol and hyperthermia potentiate gemcitabine efficacy: A Multifactorial Preclinical Evaluation in Pancreatic and Breast Cancer

Olga Wiecheć-Cudak; Aleksandra Murzyn; Gniewosz Drwięga; Aleksandra Bienia; Adam Kłóś; Dominik Robak; Krystyna Urbańska; Ivana Stanimirova-Daszykowska; Andrzej T. Słomiński; Martyna Elas; Martyna Krzykawska-Serda

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, characterized by chemoresistance and poor prognosis. Combination therapies that target multiple tumor vulnerabilities simultaneously are a promising strategy to overcome treatment limitations. This study aimed to evaluate the therapeutic potential and synergistic effects of a triple-modality treatment comprising gemcitabine (GEM), calcitriol (CAL), and hyperthermia (HT) in preclinical models of pancreatic and breast cancer.

In vitro experiments were conducted using three cancer cell lines: human PDAC (PANC-1), murine PDAC (Panc02), and murine triple-negative breast cancer (4T1). Treatments included gemcitabine (GEM), calcitriol (CAL), and hyperthermia (HT). Cell viability, apoptosis, and metabolic activity were assessed via cell counting, MTT assays, real-time live cell imaging, and flow cytometry. Protein expression of VDR and HSP70 was analyzed by Western blotting. In vivo, Panc02 tumors were orthotopically implanted in C57BL/6J mice and treated with GEM, CAL and HT. Tumor growth was monitored by ultrasound, and survival was evaluated using Cox regression models.

Triple therapy significantly reduced cell viability and metabolic activity across all models, with the strongest cytotoxic effects observed in 4T1 cells. Synergistic effects were observed at low GEM concentrations, especially in resistant PANC-1 cells. In vivo, triple therapy inhibited tumor growth, reduced peritoneal metastases, and improved survival (~ 85%), with limited systemic toxicity.

The combination of GEM, CAL, and HT shows strong synergistic anti-cancer effects both in vitro and in vivo. This triple therapy enhances treatment outcomes in resistant tumors such as PDAC and represents a clinically relevant, low-toxicity approach for multimodal cancer treatment.

Authors’ abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, characterized by chemoresistance and poor prognosis. Combination therapies that target multiple tumor vulnerabilities simultaneously are a promising strategy to overcome treatment limitations. This study aimed to evaluate the therapeutic potential and synergistic effects of a triple-modality treatment comprising gemcitabine (GEM), calcitriol (CAL), and hyperthermia (HT) in preclinical models of pancreatic and breast cancer.

In vitro experiments were conducted using three cancer cell lines: human PDAC (PANC-1), murine PDAC (Panc02), and murine triple-negative breast cancer (4T1). Treatments included gemcitabine (GEM), calcitriol (CAL), and hyperthermia (HT). Cell viability, apoptosis, and metabolic activity were assessed via cell counting, MTT assays, real-time live cell imaging, and flow cytometry. Protein expression of VDR and HSP70 was analyzed by Western blotting. In vivo, Panc02 tumors were orthotopically implanted in C57BL/6J mice and treated with GEM, CAL and HT. Tumor growth was monitored by ultrasound, and survival was evaluated using Cox regression models.

Triple therapy significantly reduced cell viability and metabolic activity across all models, with the strongest cytotoxic effects observed in 4T1 cells. Synergistic effects were observed at low GEM concentrations, especially in resistant PANC-1 cells. In vivo, triple therapy inhibited tumor growth, reduced peritoneal metastases, and improved survival (~ 85%), with limited systemic toxicity.

The combination of GEM, CAL, and HT shows strong synergistic anti-cancer effects both in vitro and in vivo. This triple therapy enhances treatment outcomes in resistant tumors such as PDAC and represents a clinically relevant, low-toxicity approach for multimodal cancer treatment.

Publication and source details

Original title: Calcitriol and hyperthermia potentiate gemcitabine efficacy: A Multifactorial Preclinical Evaluation in Pancreatic and Breast Cancer

Olga Wiecheć-Cudak; Aleksandra Murzyn; Gniewosz Drwięga; Aleksandra Bienia; Adam Kłóś; Dominik Robak; Krystyna Urbańska; Ivana Stanimirova-Daszykowska; Andrzej T. Słomiński; Martyna Elas; Martyna Krzykawska-Serda

Research Square · 2025

Author contributions

Olga Wiecheć-Cudak: OWC,Aleksandra Murzyn: AM, Gniewosz Drwięga: GD, Aleksandra Bienia: AB, Adam Kłóś: AK, Dominik Robak: DR, Krystyna Urbańska: KU, Ivana Stanimirova-Daszykowska: ISD, Andrzej T. Słomiński: ATS, Martyna Elas: ME, Martyna Krzykawska-Serda: MKS

KU: passed away before the manuscript was finalized.

martyna.krzykawska@uj.edu.pl
https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow (Poland)MNS 7/2019National Science Centre (Poland)2018/29/B/NZ5/029542022/45/B/NZ5/01695NIH2R01AR073004

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:55:55.507963+00:00

DOI: 10.21203/rs.3.rs-7593235/v1 · PMC12633502